Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E, Górniak P, Noyszewska-Kania M, Puła B, Makuch-Łasica H, Nowak G, Bluszcz A, Szydłowski M, Jabłonska E, Piechna K, Sewastianik T, Polak A, Lech-Marańda E, Budziszewska BK, Wasylecka-Juszczyńska M, Borg K, Warzocha K, Czardybon W, Gałęzowski M, Windak R, Brzózka K, Juszczyński P. Białopiotrowicz E, et al. Among authors: pula b. J Cell Mol Med. 2018 Jul;22(7):3548-3559. doi: 10.1111/jcmm.13632. Epub 2018 Apr 17. J Cell Mol Med. 2018. PMID: 29665227 Free PMC article.
Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.
Gorniak P, Budziszewska B, Pula B, Wasylecka M, Borg K, Nowak G, Makuch-Lasica H, Lech-Maranda E, Warzocha K, Juszczynski P. Gorniak P, et al. Among authors: pula b. Leuk Lymphoma. 2016;57(6):1471-3. doi: 10.3109/10428194.2015.1096355. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26414098 No abstract available.
A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
Czardybon W, Windak R, Gołas A, Gałęzowski M, Sabiniarz A, Dolata I, Salwińska M, Guzik P, Zawadzka M, Gabor-Worwa E, Winnik B, Żurawska M, Kolasińska E, Wincza E, Bugaj M, Danielewicz M, Majewska E, Mazan M, Dubin G, Noyszewska-Kania M, Jabłońska E, Szydłowski M, Sewastianik T, Puła B, Szumera-Ciećkiewicz A, Prochorec-Sobieszek M, Mądro E, Lech-Marańda E, Warzocha K, Tamburini J, Juszczyński P, Brzózka K. Czardybon W, et al. Among authors: pula b. Oncotarget. 2018 Mar 30;9(24):16917-16931. doi: 10.18632/oncotarget.24747. eCollection 2018 Mar 30. Oncotarget. 2018. PMID: 29682194 Free PMC article.
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B, Budziszewska BK, Rybka J, Gil L, Subocz E, Długosz-Danecka M, Zawirska D, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Kopacz A, Szymczyk A, Czyż J, Lech-Marańda E, Warzocha K, Jamroziak K. Puła B, et al. Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557. Anticancer Res. 2018. PMID: 29715135
Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E, Puła B, Szeremet A, Hus M, Gołos A, Hołojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Zaucha JM, Warzocha K, Jamroziak K. Iskierka-Jażdżewska E, et al. Among authors: pula b. Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911. Adv Clin Exp Med. 2019. PMID: 31199879 Free article.
The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
Salomon-Perzyński A, Bluszcz A, Krzywdzińska A, Spyra-Górny Z, Jakacka N, Barankiewicz J, Borg K, Solarska I, Szpila T, Puła B, Grosicki S, Jamroziak K. Salomon-Perzyński A, et al. Among authors: pula b. Pol Arch Intern Med. 2020 Jun 25;130(6):483-491. doi: 10.20452/pamw.15316. Epub 2020 Apr 27. Pol Arch Intern Med. 2020. PMID: 32338840 Free article.
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K. Pula B, et al. Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403. Anticancer Res. 2020. PMID: 32620653
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Puła B, Długosz-Danecka M, Salomon-Perzyński A, Szymczyk A, Subocz E, Budziszewska BK, Rybka J, Gil L, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Zaucha JM, Osowiecki M, Piszczek W, Steckiewicz P, Szukalski Ł, Hus M, Lech-Marańda E, Jurczak W, Jamroziak K. Puła B, et al. Adv Med Sci. 2020 Sep;65(2):371-377. doi: 10.1016/j.advms.2020.06.002. Epub 2020 Jul 10. Adv Med Sci. 2020. PMID: 32659728 Free article.
113 results